Syntekabio Nominates Chairman Kim Donggeon as Inside Director... Accelerates Expansion into AI Diagnosis Platform Business

Syntekabio is expanding from AI drug development into the AI-powered diagnosis platform business. The company has nominated Chairman Kim Donggeon as a candidate for inside director and is set to actively advance an AI diagnosis business that covers both humans and animals, aiming to secure new growth engines.

Syntekabio, a company specializing in AI-driven drug development, recently held a board meeting and announced that an extraordinary general meeting of shareholders will be held on September 8. At this meeting, Chairman Kim Donggeon is recommended as a candidate for inside director, and Head of Division Park Chanhee is recommended as a candidate for outside director.

Together with these executive appointments, the company plans to promote new businesses, including AI-based genomic and blood diagnostics, digital healthcare, medical big data, and animal diagnostics, with the goal of expanding into an AI diagnosis platform company.

This decision follows a recent strategic business agreement (MOU) signed with Ezen Medical Foundation. The two sides plan to jointly promote the next-generation diagnosis business by combining Ezen Medical Foundation’s medical institution network with Syntekabio’s AI technology, targeting both humans and animals.

A company representative stated, “Chairman Kim Donggeon plans to benchmark the growth model of Seegene, a leading domestic molecular diagnostics company, and expand the company’s genomic and blood-based diagnostic business nationwide. By integrating Syntekabio’s AI analytics technology, we aim to build a platform that enhances diagnostic accuracy, and extend our business beyond human diagnostics to companion animals and industrial animals, thereby consolidating our competitiveness in AI-based diagnostics.”

Regarding the nomination of Head of Division Park Chanhee as an outside director, the company also emphasized its connection to its growth strategy. The representative said, “Head of Division Park currently serves as Head of the Securities Division at Andover Asset Management. He decided to take part in management after highly valuing Syntekabio’s growth potential and the future value of the AI-based diagnostics business.”

According to the company, if additional funds are required in the course of promoting the new business, Chairman Kim Donggeon may consider participating as a strategic investor.

The representative added, “The scale and structure of any additional investments will be determined through the company’s funding plan and related procedures. We expect that combining Chairman Kim Donggeon's medical network with Syntekabio’s AI technology will further strengthen our business competitiveness.”

They continued, “We are committed to building a solid foundation for mid- to long-term growth centered on AI-based diagnostic services and enhancing our corporate value.”

Meanwhile, the appointments of Chairman Kim Donggeon and Head of Division Park Chanhee as directors are scheduled to be finalized at the extraordinary general meeting of shareholders on September 8.

Syntekabio’s strategy is to nurture the diagnostic platform business, combining medical networks and AI technology, as a new axis of growth and to simultaneously target both the human and animal diagnostic markets.

This content was produced with the assistance of AI translation services.